首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   19658篇
  免费   1898篇
  国内免费   23篇
耳鼻咽喉   246篇
儿科学   597篇
妇产科学   430篇
基础医学   2369篇
口腔科学   364篇
临床医学   2742篇
内科学   3695篇
皮肤病学   215篇
神经病学   1683篇
特种医学   773篇
外国民族医学   3篇
外科学   2545篇
综合类   489篇
一般理论   9篇
预防医学   2161篇
眼科学   629篇
药学   1613篇
中国医学   16篇
肿瘤学   1000篇
  2021年   355篇
  2020年   253篇
  2019年   373篇
  2018年   389篇
  2017年   257篇
  2016年   348篇
  2015年   346篇
  2014年   493篇
  2013年   700篇
  2012年   947篇
  2011年   1055篇
  2010年   562篇
  2009年   480篇
  2008年   869篇
  2007年   950篇
  2006年   971篇
  2005年   877篇
  2004年   851篇
  2003年   762篇
  2002年   714篇
  2001年   574篇
  2000年   596篇
  1999年   532篇
  1998年   209篇
  1997年   183篇
  1996年   171篇
  1995年   192篇
  1994年   169篇
  1993年   147篇
  1992年   412篇
  1991年   417篇
  1990年   384篇
  1989年   403篇
  1988年   344篇
  1987年   329篇
  1986年   328篇
  1985年   313篇
  1984年   264篇
  1983年   223篇
  1982年   147篇
  1981年   116篇
  1979年   194篇
  1978年   167篇
  1977年   141篇
  1976年   128篇
  1974年   159篇
  1973年   143篇
  1972年   129篇
  1971年   116篇
  1969年   111篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules.  相似文献   
4.
5.
6.
7.
Extracorporeal photopheresis (ECP) is a cell based immunomodulatory therapy in which the patient is attached intravenously to a cell separating machine. During ECP a patient's blood is collected via either a central venous access device (CVAD) or a peripherally inserted 16G arterial venous fistula needle in either one or both antecubital fossa. However, patients presenting for ECP with GVHD repeatedly present a challenge to the ECP team due to poor venous access resulting from previous therapies and skin changes. The use of peripherally inserted central venous catheters (PICCs) offers an alternative route of vascular access for this cohort of patients. Here we present a case report of a patient successfully treated with ECP following the insertion of a PICC line.  相似文献   
8.
9.
10.
Background and aimsDiabetes is one of the global health emergencies of the 21st century. This study sought to assess self-care behaviours, glycaemic control and health-related quality of life (HRQoL) of type 2 diabetes patients at a Nigerian hospital, determine factors associated with HRQoL, and assess the inter-relationship among these outcomes.MethodsThe Summary of Diabetes Self-Care Activities (SDSCA) measure was used to assess self-care behaviours; HRQoL was assessed with the Appraisal of Diabetes Scale (ADS) and SF-12v2 Health Survey. Glycaemic control was assessed with fasting blood sugar (FBS). The questionnaires were distributed to 250 eligible patients attending Endocrinology clinic at the University of Uyo Teaching Hospital, Akwa Ibom State, Nigeria.ResultsMean scores (±SD) of self-care behaviours were 4.0 ± 1.3, 3.9 ± 1.0, 2.4 ± 1.2, 1.0 ± 1.1, and 2.5 ± 2.1 for general diet, specific diet, exercise, blood glucose monitoring, and foot care respectively. Mean FBS was 7.1 ± 2.1 mmol/L. Mean ADS score was 18.1 ± 4.2. The physical and mental component summary scores were 47.84 ± 8.21 and 45.66 ± 8.74 respectively. HRQoL was significantly associated with patient socio-demographic (except gender) and clinical variables (p < 0.05). Self-care activities, FBS and HRQoL were significantly inter-correlated (rs ?0.31 to 0.68; p < 0.01, p < 0.001).ConclusionsPatients were more adherent to diet recommendations than to other aspects of self-care. Though most patients had adequate glucose control, the presence of diabetes had a negative impact on the mental component of health. HRQoL was affected by most of the patient-related variables. Interventions to improve adherence to self-care are recommended to achieve good glycaemic control and improve HRQoL.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号